337
edits
Changes
Jump to navigation
Jump to search
no edit summary
*Dates
*MeSH (Medical Subject Headings)
==== Study ====
The corresponding nodes are:
-<id_info>
<org_study_id>NCRR-M01RR01070-0506</org_study_id>
<secondary_id>M01RR001070</secondary_id>
<nct_id>NCT00000102</nct_id>
</id_info>
<brief_title>Congenital Adrenal Hyperplasia: Calcium Channels as Therapeutic Targets</brief_title>
-<oversight_info>
<authority>United States: Federal Government</authority>
</oversight_info>
-<brief_summary>
<textblock> This study will test the ability of extended release nifedipine (Procardia XL), a blood pressure medication, to permit a decrease in the dose of glucocorticoid medication children take to treat congenital adrenal hyperplasia (CAH). </textblock>
</brief_summary>
-<detailed_description>
<textblock> This protocol is designed to assess both acute and chronic effects of the calcium channel antagonist, nifedipine, on the hypothalamic-pituitary-adrenal axis in patients with congenital adrenal hyperplasia. The multicenter trial is composed of two phases and will involve a double-blind, placebo-controlled parallel design. The goal of Phase I is to examine the ability of nifedipine vs. placebo to decrease adrenocorticotropic hormone (ACTH) levels, as well as to begin to assess the dose-dependency of nifedipine effects. The goal of Phase II is to evaluate the long-term effects of nifedipine; that is, can attenuation of ACTH release by nifedipine permit a decrease in the dosage of glucocorticoid needed to suppress the HPA axis? Such a decrease would, in turn, reduce the deleterious effects of glucocorticoid treatment in CAH. </textblock>
</detailed_description>
==== Location ====
